Analogies for Beam Therapeutics (BEAM):

• It's like CRISPR Therapeutics (CRSP), but using a newer, more precise 'base editing' technology to fix genetic errors.
• Think of it as a pioneer in gene editing, similar to how Moderna (MRNA) pioneered mRNA technology, but focused on making precise 'base edits' to DNA for therapeutic purposes.
• Similar to the original CRISPR gene-editing companies (e.g., CRISPR Therapeutics), but specializing in a more refined 'base editing' approach that avoids cutting DNA.

• BEAM-101: An investigational *ex vivo* base editing program for sickle cell disease and beta-thalassemia, designed to modify hematopoietic stem cells to reduce disease symptoms.
• BEAM-201: An investigational *ex vivo* multiplex base edited CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia, engineered to target specific cancer markers.
• BEAM-302: An investigational *in vivo* base editing therapy for Glycogen Storage Disease type Ia (GSDIa), delivered to the liver to correct the underlying genetic mutation.

Beam Therapeutics (symbol: BEAM) is a clinical-stage biotechnology company primarily focused on developing precision genetic medicines through base editing. As such, it does not currently have approved products for sale directly to individuals (patients) or healthcare providers.

Instead, Beam Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies that license its proprietary base editing technology or collaborate on research and development programs. Therefore, its major "customers" are other companies within the biopharmaceutical industry.

Major Customer Companies:

• Pfizer Inc. (Symbol: PFE)
  • In January 2022, Beam Therapeutics announced a significant global collaboration with Pfizer to develop novel in vivo base editing programs for three undisclosed rare diseases. This collaboration includes upfront payments, an equity investment from Pfizer, and potential milestone payments and royalties on future product sales, making Pfizer a key financial partner and "customer" for Beam's technology.
• Verve Therapeutics, Inc. (Symbol: VERV)
  • Beam has a long-standing strategic collaboration with Verve Therapeutics. Verve utilizes Beam's base editing technology under license for its programs aimed at treating cardiovascular diseases. This collaboration involves milestone payments and royalties to Beam for the use of its technology.

John Evans, Chief Executive Officer and Board Member

Mr. Evans joined Beam Therapeutics in 2017 as CEO. He previously served as an early employee and member of the leadership team at Agios Pharmaceuticals, where he was Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, he provided strategic and operational leadership for a portfolio of IDH inhibitors and helped initiate and lead a landmark alliance with Celgene, which resulted in over $600 million of funding and investments across multiple research collaborations. He also co-led Agios's expansion into rare genetic diseases. Prior to Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company, and MedImmune. He also served as interim CEO for Prime Medicine.

Terry-Ann Burrell, Chief Financial Officer

Ms. Burrell joined Beam Therapeutics as Chief Financial Officer in 2019. Prior to Beam, she spent 11 years with J.P. Morgan, most recently as a Managing Director in the healthcare investment banking group, where she covered the biotechnology and pharmaceutical industries. During her tenure at J.P. Morgan, she helped execute over $10 billion in equity and equity-linked financings and more than $50 billion in M&A transactions. Earlier in her career, Ms. Burrell worked in equity research at Citigroup, covering specialty pharmaceuticals and generics.

Giuseppe Ciaramella, Ph.D., President

Dr. Ciaramella is the President of Beam Therapeutics. He has over 20 years of drug discovery experience and has held several leadership roles at companies including Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer, and Merck. Before joining Beam, Dr. Ciaramella was the Chief Scientific Officer of the Infectious Diseases division of Moderna Therapeutics, where he was instrumental in generating some of the first mRNA vaccines to be dosed in humans. He is also a co-founder and CEO of Orbital Therapeutics.

Suzanne Fleming, Senior Vice President, Finance

Ms. Fleming brings more than 25 years of experience in finance leadership roles within the life science industry to Beam Therapeutics. Before joining Beam, she was Senior Vice President, Finance and Treasurer at Epizyme, Inc. Prior to Epizyme, she was Vice President, Finance at Foundation Medicine, where she worked closely with Roche after their purchase of a majority stake in the company. Ms. Fleming also held senior finance positions at Aegerion Pharmaceuticals, AVEO Pharmaceuticals, Transform Pharmaceuticals, and Transkaryotic Therapies.

Manmohan Singh, Ph.D., Chief Technology Officer

Dr. Singh is the Chief Technology Officer at Beam Therapeutics. He has over 24 years of experience in drug discovery and development. Prior to Beam Therapeutics, Dr. Singh was the Global Head of Drug Product Development at Takeda Vaccines, where he oversaw the drug product development of all vaccine programs. His experience also includes roles at Novartis and Chiron Corporation.

1. Clinical and Regulatory Risk: Beam Therapeutics is a clinical-stage biotechnology company without any approved products, meaning its commercial success is entirely dependent on the successful development, regulatory approval, and commercialization of its product candidates. This process is inherently long, costly, and subject to significant uncertainty. Clinical trials can fail at any stage, or encounter unexpected safety issues, undesirable side effects, or a lack of efficacy, which could delay or prevent regulatory approval. The novelty of Beam's base editing technology, while promising, also subjects it to heightened regulatory scrutiny from authorities like the FDA, potentially leading to delays in trial approvals and development timelines. Challenges in patient conditioning for blood diseases and slow trial development have also been noted, contributing to delays in key data readouts.
2. Financial Risk and Need for Additional Funding: As a company in the research and development phase, Beam Therapeutics consistently incurs substantial operating losses and does not generate revenue from product sales. Although the company has a cash runway extending into 2026 or potentially 2028, it will require substantial additional capital to fund its extensive pipeline and advance its therapies through clinical trials and toward commercialization. The ability to raise this capital is dependent on market conditions and investor sentiment, and any inability to secure funding when needed could force the company to delay, reduce, or eliminate its development programs or future commercialization efforts, potentially leading to significant shareholder dilution. Negative insider sentiment, driven by significant open-market selling from key executives, may also signal a lack of confidence in the company's future prospects.
3. Competition and Evolving Technology Risk: The field of gene editing is rapidly evolving and highly competitive, with numerous biotechnology and pharmaceutical companies developing their own gene-editing and CRISPR-based therapies. Beam's ability to differentiate itself will depend on demonstrating superior safety, durability, and cost-effectiveness compared to existing or emerging treatments. There is a continuous risk that other gene editing technologies could be discovered that offer significant advantages over base editing, or that competitors could bring similar or more effective therapies to market faster, thereby reducing the commercial potential and market share of Beam’s product candidates.

Addressable Markets for Beam Therapeutics' Main Products or Services

• BEAM-101 (Sickle Cell Disease - SCD):
  • The global sickle cell disease treatment market was estimated at USD 2.75 billion in 2023 and is projected to reach USD 7.42 billion by 2030, growing at a CAGR of 15.7% from 2024 to 2030.
  • Another estimate for the global market size was USD 2.25 billion in 2022, projected to grow to USD 9.84 billion by 2030, at a CAGR of 20.1% during 2023-2030.
  • The U.S. sickle cell disease treatment market was valued at USD 861.84 million in 2024 and is projected to reach approximately USD 3,789.17 million by 2034, with a CAGR of 15.96% from 2025 to 2034.
  • North America held the largest revenue share of 36% in the global market in 2024.
• BEAM-302 (Alpha-1 Antitrypsin Deficiency - AATD):
  • The global Alpha-1 Antitrypsin Deficiency Disease Treatment Market was valued at USD 3.2 billion in 2024 and is projected to reach USD 8,375.42 million by 2032, growing at a CAGR of 12.78%.
  • Another source indicates the global market valuation is expected to increase from USD 3.52 billion in 2024 to USD 13.5 billion by 2035, with a CAGR of 12.98% from 2025 to 2035.
  • North America dominated the market with a 42% share in 2024.
• BEAM-201 (T-cell Acute Lymphoblastic Leukemia - T-ALL/T-cell Lymphoblastic Lymphoma - T-LL):
  • The global Acute Lymphoblastic Leukemia (ALL) therapeutics market size was valued at USD 3 billion in 2023 and is predicted to grow at a 6.8% CAGR between 2024 and 2032.
  • The global Acute Lymphoblastic Leukemia market size is estimated at USD 3.72 billion in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 7.40% from 2025 to 2033.
  • North America is reported to hold the major market share for more than 40% of the global revenue, with a market size of USD 1376.40 million in 2025.
  • Another report states the global Acute Lymphoblastic Leukemia Market was valued at USD 3.52 billion in 2024 and is projected to reach USD 6.98 billion by 2034, growing at a CAGR of 7.1% during the forecast period (2025-2034).
  • The U.S. acute lymphocytic leukemia therapeutics market size is expected to reach around USD 3.26 billion by 2034 and is growing at a CAGR of 10.5% from 2024 to 2034.
• BEAM-301 (Glycogen Storage Disease Type 1a - GSD1a):
  • Null

• Advancement and Potential Commercialization of BEAM-101 for Sickle Cell Disease (SCD): BEAM-101 is Beam Therapeutics' lead hematology program for severe sickle cell disease. The company has achieved its adult enrollment target in the BEACON Phase 1/2 trial, with updated data expected in mid-2025, and further updates at the ASH meeting in December 2025. BEAM-101 has also received FDA Orphan Drug Designation, which provides benefits such as tax credits for clinical trials, exemption from certain FDA fees, and potentially seven years of market exclusivity upon approval. Successful clinical outcomes and eventual regulatory approval for BEAM-101 would be a significant revenue driver through potential product sales.
• Clinical Progression of BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD): BEAM-302, an *in vivo* base editing program for Alpha-1 Antitrypsin Deficiency, is a top priority for Beam Therapeutics and represents the first clinical program to directly correct a disease-causing mutation *in vivo*. The company expects to report initial data from multiple cohorts of the Phase 1/2 study in AATD in early 2026, following positive initial data and advancement to its fourth cohort in Q1 2025. Positive clinical data and progression towards later-stage trials or potential partnerships for BEAM-302 could generate substantial milestone payments and future royalties.
• Development of the ESCAPE Platform and BEAM-103: Beam's ESCAPE technology aims to expand the addressable patient population for gene editing by potentially eliminating chemotherapy, which could significantly increase the market for their therapies. The company expects to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103, an ESCAPE monoclonal antibody, by the end of 2025. The success of the ESCAPE platform in enabling non-genotoxic conditioning could open up significant new markets and enhance the revenue potential of Beam's gene-editing programs.
• Advancement of BEAM-301 for Glycogen Storage Disease Type Ia (GSD1a): BEAM-301 is Beam's second *in vivo* base editing program to reach clinical testing, with patient dosing in the Phase 1/2 clinical trial expected to commence in early 2025. Successful progression of BEAM-301 through clinical development could contribute to future revenue through milestone payments from collaborations or potential product sales in this rare genetic disorder.
• Strategic Collaborations and Licensing Agreements: As a pre-commercial biotechnology company, Beam Therapeutics currently generates revenue primarily through strategic collaborations and licensing agreements. These agreements often include upfront payments, research funding, milestone payments, and potential royalties on future product sales. Beam has secured significant upfront payments from agreements with partners such as Pfizer, Apellis, Verve, and Sana, and continues to engage in strategic initiatives and partnerships to enhance research and development efforts and provide additional funding. Future agreements and the achievement of milestones within existing collaborations will continue to be a crucial revenue driver.

Share Issuance

• Beam Therapeutics completed an underwritten public offering in March 2025, generating approximately $500.0 million in gross proceeds through the issuance of 16,151,686 shares of common stock and 1,404,988 pre-funded warrants.
• In October 2023, Eli Lilly and Company made a $50 million equity investment in Beam Therapeutics as part of a broader collaboration and license agreement.
• As an upfront payment for an acquisition finalized on July 1, 2025, Beam issued 403,128 shares of common stock to the acquired company's shareholders.

Inbound Investments

• Beam Therapeutics received an upfront payment of $300 million from Pfizer in February 2022 as part of a four-year research collaboration aimed at developing in vivo base editing programs for rare genetic diseases.
• In October 2023, Beam received a $200 million upfront payment and a $50 million equity investment from Eli Lilly and Company, with eligibility for up to an additional $350 million in future development-stage payments.

Outbound Investments

• In February 2021, Beam Therapeutics acquired Guide Therapeutics, Inc. for an upfront consideration of $120 million, paid in Beam common stock. GuideTx stockholders are also eligible for up to $320 million in additional milestone payments, payable in Beam common stock.
• On July 1, 2025, Beam Therapeutics acquired an early-stage life sciences company, issuing 403,128 shares of its common stock as an upfront payment, with potential future milestone payments of up to $89 million.

Capital Expenditures

• Beam Therapeutics reported capital expenditures of approximately $14.18 million over the last 12 months leading up to November 2025.
• The company's cash reserves are anticipated to fund its operating expenses and capital expenditure requirements into 2028.
• Capital expenditures are primarily focused on advancing key clinical programs such as BEAM-101 for sickle cell disease, the ESCAPE conditioning platform, BEAM-301, and BEAM-302, as well as supporting internal manufacturing capabilities, including its North Carolina facility.